M. Bafadhel (Oxford (Oxfordshire), United Kingdom), P. Kirkham (Wolverhampton (West Midlands), United Kingdom)
LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE)
K. Gashynova (Dnipro, Ukraine)
|  |
Use of a clothing adherent respiratory sensor to continuously monitor COPD patients at home
N. Moraveji (San Francisco, United States of America), R. Murray (San Francisco, United States of America), M. Holt (San Francisco, United States of America), J. Hollenbach (San Francisco, United States of America), P. Golz (San Francisco, United States of America), M. Crocker (San Diego, United States of America), H. White (San Diego, United States of America), M. Phillips (San Diego, United States of America)
| |
Acute exacerbation of COPD in Emergency Room: just COPD exacerbations?
M. Tine (Padova, Italy), G. Turato (Padova, Italy), K. Lokar Oliani (Padova, Italy), E. Bazzan (Padova, Italy), U. Semenzato (Padova, Italy), D. Biondini (Padova, Italy), M. Bonato (Padova, Italy), M. Saetta (Padova, Italy), M. Cosio (Montreal, Canada)
| |
Cough reflex sensitivity: association with exacerbation frequency in chronic obstructive pulmonary disease
P. Cho (London, United Kingdom), H. Fletcher (London, United Kingdom), I. Patel (London, United Kingdom), C. Jolley (London, United Kingdom), R. Turner (London, United Kingdom), S. Birring (London, United Kingdom)
| |
Antibiotic choice and repeat prescriptions in infective COPD exacerbations
M. Stolbrink (Liverpool, United Kingdom), L. Bonnett (Liverpool, United Kingdom), J. Blakey (Perth, Australia)
| |
Predicting early vs late vs no re-exacerbation in COPD patients:Analysis of ECLIPSE cohort
M. Fahey (London, United Kingdom), W. Meeraus (London, United Kingdom), C. El Baou (London, United Kingdom), H. Mullerova (London, United Kingdom), E. M. Hessel (London, United Kingdom), W. A. Fahy (London, United Kingdom)
| |
Predictors of mortality in COPD patients after hospitalization due to an exacerbation
C. Lahosa (Valencia , Spain), L. Fernandez-Presa (Valencia , Spain), I. Bocigas (Valencia , Spain), J. Signes-Costa Miñana (Valencia , Spain), B. Safont (Valencia , Spain), C. Gonzalez (Valencia , Spain), E. Servera (Valencia , Spain)
|  |
Detecting COPD exacerbations through Prevexair App.
S. Esmaili (Madrid, Spain), J. Rodriguez Hermosa (Madrid, Spain), A. Fuster Gomila (Palma De Mallorca, Islas Baleares, Spain), L. Puente Maestu (Madrid, Spain), C. Amado Diago (Santander, Cantabria, Spain), F. Callejas González (Albacete, Albacete, Spain), R. Malo De Molina Ruiz (Madid, Madrid, Spain), A. Montero Pacios (Madid, Madrid, Spain)
| |
Characterisation of the bronchial epithelium in COPD frequent exacerbators
A. Higham (Manchester, United Kingdom), J. Dungwa (Manchester, United Kingdom), N. Jackson (Manchester, United Kingdom), D. Cunoosamy (Molndal, Sweden), D. Singh (Manchester, United Kingdom)
| |
COPD Assessment Test responsiveness during acute exacerbations recovery: the role of body mass index
C. Freitas (Porto, Portugal), J. Dias (Porto, Portugal), P. Leuschner (Porto, Portugal)
| |
IMPACT OF TELEMONITORING ON PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE
a. fernandez (BILBAO, Spain), R. Sanchez (BILBAO, Spain), M. Pastor (BILBAO, Spain), V. Bustamante (BILBAO, Spain), B. Galaz (BILBAO, Spain), C. Sancho (BILBAO, Spain), A. Sagarna (BILBAO, Spain), A. Mardones (BILBAO, Spain), I. Maider (BILBAO, Spain)
| |
Does a Tailored Intervention to Promote Adherence in Patients with Chronic Lung Disease Affect Exacerbations?
C. Gregoriano (Liestal, Basel, Switzerland), T. Dieterle (Liestal, Basel, Switzerland), A. Breitenstein (Liestal, Switzerland), S. Dürr (Liestal, Switzerland), A. Baum (Liestal, Switzerland), S. Giezendanner (Basel, Switzerland), S. Maier (Liestal, Switzerland), A. Leuppi-Taegtmeyer (Basel, Switzerland), I. Arnet (Basel, Switzerland), K. Hersberger (Basel, Switzerland), J. Leuppi (Liestal, Basel, Switzerland)
| |
Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial
B. Hartley (Twickenham, United Kingdom), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), P. Jones (Brentford, United Kingdom), C. Crim (Research Triangle Park, NC, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Singh (Manchester, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), N. Barnes (Brentford and London, United Kingdom)
| |
PEARL SCORE PREDICTION FOR MORTALITY IN SEVERE ACUTE COPD RE-EXACERBATION
B. Recio Moreno (Madrid, Spain), W. Giron Matute (Madrid, Spain), A. Cerezo Lajas (Madrid, Spain), E. Rodríguez Jimeno (Madrid, Spain), V. Gallo González (Madrid, Spain), Z. Ji (Madrid, Spain), C. Castro Riera (Madrid, Spain), L. Puente Maestu (Madrid, Spain)
| |
Regional analysis of COPD exacerbation rates in the DYNAGITO trial
K. Rabe (Grosshansdorf, Germany), J. Wedzicha (London, United Kingdom), P. Calverley (Liverpool, United Kingdom), A. De La Hoz (Ingelheim am Rhein, Germany), F. Voß (Ingelheim am Rhein, Germany), A. Anzueto (San Antonio, United States of America), C. Jenkins (Sydney, Australia)
| |
Transcriptomic footprint of COPD patients with well-defined frequent severe exacerbations.
S. Pascual (Barcelona, Spain), P. Puigdevall (Barcelona, Spain), C. Casadevall (Barcelona, Spain), E. Barreiro (Barcelona, Spain), R. Castelo (Barcelona, Spain), J. Gea Guiral (Barcelona, Spain)
| |
Simultaneous assessment of DNA damage and antioxidant enzyme activity in COPD exacerbations
B. Antus (Budapest, Hungary), C. Paska (Budapest, Hungary), I. Barta (Budapest, Hungary)
| |
Analysis of cytokine gene expression after treatment and pulmonary rehabilitation of acute exacerbation in COPD
C. Páska (Budapest, Hungary), I. Barta (Budapest, Hungary), Z. Kelemen (Budapest, Hungary), K. Kelemen (Budapest, Hungary), J. Varga (Budapest, Hungary), B. Antus (Budapest, Hungary)
| |